Who
Glenn Reicin
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Harmony Biosciences Holdings; Chief Financial Officer, Sigilon Therapeutics.
In numbers
- Trades disclosed
- 3
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 11 Feb 2021
- Last trade
- 14 Apr 2026
- Last filed
- 18 May 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Apr 2026filed 18 May 2026 | HRMY Harmony Biosciences Holdingsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —164,309 at $0.00 | filing |
| 14 Apr 2026filed 18 May 2026 | HRMY Harmony Biosciences Holdingsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —164,309 at $0.00 | filing |
| 11 Feb 2021filed 16 Feb 2021 | Sigilon Therapeuticsoption or derivative | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.